Thread by @sailorrooscout

Look at those antibodies!
The latest from the New England Journal of Medicine shows the effective neutralization assessed with serum from participants vaccinated with 2 doses of Pfizer’s BNT162b2 COVID-19 vaccine against VOCs B.1.1.7, B.1.351, and P.1.
nejm.org/doi/full/10.10…

To analyze effects on neutralization elicited by Pfizer’s vaccine, researchers engineered spike mutations from the from the current VOC lineages. They then performed 50% plaque reduction neutralization testing (PRNT50) using 20 serum samples that had been obtained from

15 participants in the pivotal trial 2 or 4 weeks after the administration of the second dose of 30 μg of Pfizer’s vaccine (which occurred 3 weeks after the first immunization). All the serum samples efficiently neutralized their isolate and all the viruses with variant spikes.

Almost all of them did so at titers higher than 1:40. This demonstrates how effective Pfizer’s vaccine is at neutralizing these variants. What we are seeing essentially is only a 2-3 fold reduction even for variant B.1.351!

Pfizer’s vaccine essentially crush these variants in the best of ways (yeah, I said it). Not to mention, researchers also noted T-cell immunity may also be involved in protection, and Pfizer’s vaccine elicits CD8+ T-cell responses that recognize multiple variants. Need more data.

Supplementary Appendix can be found here: nejm.org/doi/suppl/10.1…